Observational studyESC heart failure2026
Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair.
Observational study in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsIntraprocedural assessment of residual mitral regurgitation (MR) is crucial for the success of transcatheter edge-to-edge mitral valve repair (M-TEER), yet challenging in the case of ambiguous echocardiographic findings. Monitoring left atrial (LA) pressure can complement the evaluation of residual MR after device placement. This study aimed to determine the prognostic impact of intraprocedural changes in LA pressure on the clinical outcome following M-TEER.
methodsWe enrolled 299 patients undergoing M-TEER for primary or secondary MR in a prospective observational study. During the procedure, LA mean (LAmP) and LA v wave pressure (LAvP) were recorded before and after device implantation. The primary endpoint was death or hospitalization for heart failure during a 2-year follow-up.
resultsMean age of the study population was 76.6 ± 8.2 years. Secondary mitral regurgitation was identified in 62.9% of the patients. Reduction to MR grade I or II was achieved in 95.3% of cases. During M-TEER, LAvP decreased from 30.5 ± 15.0 to 23.2 ± 10.4 mmHg (P < .001) after device implantation, accompanied by a modest reduction of LAmP from 16.6 ± 6.3 to 15.3 ± 5.9 mmHg (P = .006). LAvP post M-TEER was a strong predictor of death or hospitalization for heart failure in both univariate and multivariate analysis, independent of echocardiographic MR severity (hazard ratio per 10 mmHg 1.37 [1.15-1.63], P < .001 and 1.29 [1.06-1.57], P = .012). Residual LAvP below 25 mmHg was strongly associated with a favourable outcome irrespective of residual echocardiographic MR grade, including patients with residual MR grade I and II.
conclusionHigh residual LAvP predicts death or hospitalization for heart failure after M-TEER. LAvP after device implantation provides incremental prognostic information beyond echocardiographic MR grading and may therefore assist intraprocedural decision-making during M-TEER.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.